Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
49 Results for "
enpp-1
" in MedChemExpress (MCE) Product Catalog:
Products (49)
49 Results for "enpp-1" in MCE Product Catalog:
3
3 Cited Publications
Target:
Research Areas:
Enpp-1-IN-1 is an effective selective enpp-1 (nucleotide pyrophosphatase-phosphodiesterase 1) inhibitor [1].
1
1 Cited Publications
Target:
Research Areas:
Enpp-1-IN-14 (Compound 015) is a potent Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) inhibitor with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity [1].
1
1 Cited Publications
Cat. No.: HY-P700709
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: enpp1; Nucleotide Diphosphatase; Prev. PDNP1; NPPase; Prev. M6S1; Membrane Component, Chromosome 6, Surface Marker 1; Prev. NPPS; Membrane Component Chromosome 6 Surface Marker 1; PC-1; Plasma-Cell Membrane Glycoprotein 1; PCA1; Alkaline Phosphodiesterase
Cat. No.: HY-176708
CAS No.: 2965301-60-2
Target:
Research Areas:
ISM5939 is an orally active and selective ENPP1 inhibitor with an IC50 of 0.63 nM for 2,3-cGAMP degradation and 9.28 nM for ATP hydrolysis. ISM5939 has antitumor activity [1].
Cat. No.: HY-141831
CAS No.: 2298390-71-1
Target:
Research Areas:
STF-1084 is a specific, cell-impermeable, competitive inhibitor of ENPP1 (Ki = 33 nM). STF-1084 increases extracellular cGAMP concentrations by preventing its degradation by ENPP1, thereby enhancing immune infiltration. STF-1084 acts synergistically with ionizing radiation (IR) and cGAMP to delay tumor progression. STF-1084 can be used to study cancers with low immunogenicity [1].
Target:
Research Areas:
Enpp-1-IN-12 (compound 43) is a potent and orally active ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor, with a Ki of 41 nM. Enpp-1-IN-12 exhibits anti-tumor activity [1].
Cat. No.: HY-163343
CAS No.: 3029600-37-8
Target:
Research Areas:
Enpp-1-IN-20 (Compound 31) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor, with an IC50 of 0.09 nM. Enpp-1-IN-20 has strongest inhibitory activity in the cell-based assay, with an IC50 of 8.8 nM. Enpp-1-IN-20 has significant potency in both ENPP1 inhibition and STING pathway stimulation in vitro. Enpp-1-IN-20 can be used for the research of cancer [1].
Target:
Research Areas:
Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence [1].
Target:
Research Areas:
Enpp-1-IN-21 (compound 4g) is an inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), with IC50 values for ENPP1 and ENPP3 at 0.45 and 0.19 μM, respectively [1].
Target:
Research Areas:
Enpp-1-IN-2 (Compound C) is a potent ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) inhibitor with IC50 values of 0.26, 0.48 and 2.0 μM evaluated by means of TG-mAMP, pNP-TMP, and ATP assays, respectively. TG (Tokyo Green)-mAMP: a newly synthesized sensitive ENPP1 fluorescence probe [1].
Target:
Research Areas:
Enpp-1-IN-10 (compound 1) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 3.866 μM. Enpp-1-IN-10 can be used for researching anticancer [1].
Target:
Research Areas:
Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders [1].
Cat. No.: HY-169804
CAS No.: 2803505-90-8
Target:
Research Areas:
ENPP3 Inhibitor 1 is a selective inhibitor of ENPP3, with IC50s of 0.15 µM (ENPP3) and 41.4 µM (ENPP1) respectively. ENPP3 Inhibitor 1 shows anti-tumor activities against breast cancer and cervical cancer [1].
Cat. No.: HY-176296
CAS No.: 2687222-58-6
Synonyms: SR-8541A
Target:
Research Areas:
Vizenpistat (SR-8541A) is an orally active ENPP1 inhibitor. Vizenpistat increases cGAMP levels, blocks 2′3′-cGAMP hydrolysis, inhibits adenosine production, regulates innate immune signaling mediated by the STING pathway, and modulates anti-tumor immune responses. Vizenpistat is applicable to research related to breast cancer and metastatic microsatellite-stable colorectal cancer [1] .
Cat. No.: HY-143255
CAS No.: 2631703-04-1
Target:
Research Areas:
Enpp-1-IN-11 (compound 23) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 45 nM. Enpp-1-IN-11 exhibits low clearance in human and mouse liver microsomes, good plasma stability in human and mouse plasma. Enpp-1-IN-11 can be used for researching anticancer [1].
Cat. No.: HY-175478
CAS No.: 3105103-33-8
Target:
Research Areas:
Enpp-1-IN-27 is a selective ENPP1 inhibitor with an IC50 of 14.68 nM, exhibiting approximately 410-fold selectivity against ENPP2 and 10-fold selectivity against ENPP3. Enpp-1-IN-27 stabilizes cGAMP levels and activates the STING pathway, promoting cytokine release and enhancing innate immune responses. Enpp-1-IN-27 induces ISRE activation and amplified cGAMP-mediated immune responses and shows the desired antitumor efficacy in the 4T1 and CT26 syngeneic mouse models. Enpp-1-IN-27 can used for the studies of breast cancer and colon cancer [1].
Cat. No.: HY-153334
CAS No.: 2756218-99-0
Target:
Research Areas:
Enpp-1-IN-15 (Compound 88a) is an Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp-1) Inhibitor, with a Ki value of 0.00586 nM [1].
Cat. No.: HY-176828
Target:
Research Areas:
Enpp-1-IN-28 is a ENPP1 inhibitor at the molecular and cellular levels, with IC50 values of 0.188 µM and 0.732 µM, respectively. Enpp-1-IN-28 upgrades the expression levels of IFN-β in vivo by preventing the ENPP1 from hydrolyzing the cGAMP to stimulate a more potent innate immune response. Enpp-1-IN-28 can be used for the study of metastatic breast cancer [1].
Cat. No.: HY-176874
CAS No.: 2944114-41-2
Target:
Research Areas:
Enpp-1-IN-29 (Compound 1) is a highly selective ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor (IC50=0.05 nM). Enpp-1-IN-29 is promising for research of ENPP1-overexpressing cancers (e.g., breast cancer, head/neck cancer, metastatic chromosome-unstable tumors) and immune-related diseases (e.g., autoimmune disorders, tumor immune evasion) [1].
Cat. No.: HY-RS04387
Target:
Research Areas:
ENPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
